{"id":"W4292565458","doi":"10.1200/jco.22.00294","title":"Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastrointestinal Tumor Research and Treatment","field":"Medicine","cited_by":111,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Deciphera Pharmaceuticals; U.S. Department of Veterans Affairs","keywords":"Medicine; Sunitinib; GiST; Internal medicine; Hazard ratio; Imatinib; Clinical endpoint; Gastroenterology; Tyrosine-kinase inhibitor; Imatinib mesylate; Oncology; Progression-free survival; Surgery; Randomized controlled trial; Confidence interval; Cancer; Stromal cell; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001408968,0.001110541,0.002274972,0.0002867179,0.0003414854,0.0008796821,0.0004798915,0.001156708,0.005730418],"category_scores_gemma":[0.001351686,0.0004358231,0.002213417,0.0002484823,0.0007535265,0.000939832,0.0002870609,0.001919619,0.0006910615],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007485963,"about_ca_system_score_gemma":0.0009235773,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005038509,"about_ca_topic_score_gemma":0.001769552,"domain_scores_codex":[0.9993476,0.0003465565,0.00004899407,0.0001257963,0.00004270141,0.00008835567],"domain_scores_gemma":[0.9994026,0.0001900374,0.0001408702,0.00003554807,0.00002764948,0.0002033393],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9765425,0.003836521,0.000789649,0.0004025582,0.0007739749,0.00003956311,0.00003606878,0.0003672646,0.001556489,0.0000898472,0.0007204177,0.01484522],"study_design_scores_gemma":[0.9170039,0.07816223,0.002321254,0.00002478588,0.0004904568,0.00006656587,0.00001933311,0.000605041,0.0003461624,0.0001865208,0.00075886,0.00001485502],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9892941,0.0044466,0.0004241735,0.000559376,0.0004086634,0.002157901,0.0007282939,0.0000973453,0.00188361],"genre_scores_gemma":[0.9929174,0.001375411,0.0006496931,0.0006600767,0.0002685344,0.002013392,0.0005657637,0.00001063748,0.00153904],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005730418,"threshold_uncertainty_score":0.01917017,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1062182956752445,"score_gpt":0.4614978297003581,"score_spread":0.3552795340251135,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}